

ESPERION 3Q20 CONFERENCE CALL

November 2, 2020



SAFE HARBOR

FORWARD- LOOKING STATEMENTS

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the clinical development and commercialization plans for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, including ESPERION's timing, designs, plans for announcement of results regarding its CLEAR Outcomes study and other ongoing clinical studies for bempedoic acid tablet and the bempedoic acid / ezetimibe combination fixed dose tablet, timing for the review and approval of expanded indications for their effect on cardiovascular events, ESPERION's expectations for the market for medicines to lower LDL-C, including the commercial launch and market adoption of bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet in the United States and European Union, and ESPERION's financial outlook, including expectations for future revenues from its product sales, partnership collaborations and other sources. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause ESPERION's actual results to differ significantly from those projected, including, without limitation, delays or failures in ESPERION's clinical development and commercialization plans, or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, that Otsuka and DSE are able to successfully commercialize its products, the impact of COVID-19 on our business, clinical activities and commercial development plans, and the risks detailed in ESPERION's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and ESPERION disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

BUSINESS OVERVIEW

Tim M. Mayleben, President & CEO



THE POWER OF SINGULAR FOCUS AND MOMENTUM



**After decreasing,
CDC says heart disease deaths will remain
the leading cause of death and increase
25% by 2030**

***TODAY IS THE FIRST DAY OF COMMERCIAL
AVAILABILITY OF OUR MEDICINES IN EUROPE!***



SUPPORT IS GROWING ACROSS STAKEHOLDER GROUPS

AACE Lipid Guidelines

Patient Advocacy





CLEAR OUTCOMES TRIAL DESIGN PUBLISHED LAST WEEK

First-of-its-kind cardiovascular outcomes trial, following more than 14,000 patients with documented statin intolerance

There are approximately 10 million statin intolerant patients in the US.

We've reached over 50% of MACE endpoints to date

ESPERION[®]

COMMERCIAL PROGRESS

Mark Glickman, CCO





OUR REALITY: THIS NO LONGER EXISTS...




1271194493

SCRIPTS (RPE) GREW OVER 500% FROM 2Q 2020

While New-to-Brand in overall LDC-C market was down ~30%

Quarterly Franchise RPE Trend



Franchise RPE Trend Since Launch



*Based on Symphony data



POSITIVE REACTIONS FROM HEALTH CARE PROVIDERS

"A lot of patients are interested in this when I present it to them because it is an oral formulation"

Cardiologist

"One nice thing about these medicines is that they are just one dose. It really clears up the confusion when prescribing"

Primary Care Physician

"It's nice to have a new class of medication for cholesterol control. It's much better tolerated than current statins are and it's very effective. It can be combined with statins or combined with ezetimibe. It looks like a winner"

Cardiologist

WE'VE LEARNED NOTHING BEATS FACE-TO-FACE

Our team is committed to reaching HCPs on their terms, in their time

We believe we are leading the industry at 70% in person visits


Total biopharma details reached 85% vs. baseline of which remote details account for approximately 54% of all prescriber details

Specialty in-person details remain at approximately 48% of baseline with Oncology and Primary care at 22% and 42% respectively

Source: IQVIA



WE'VE LAUNCHED OUR FIRST DIRECT TO CONSUMER CAMPAIGN



Pay as little as \$10*
NEXLETOL
(bempedoic acid) tablets

LEARN MORE >

*Up to a 3-month supply. For privately or commercially insured patients. Restrictions apply. See Terms and Conditions. © 2020 Esperion Therapeutics, Inc. All rights reserved. NEXL 20-0017, 02/20/20



Lowering bad cholesterol can be a never-ending cycle



One segment of the graphic highlights a time to connect with the real image appearing in the video.

NEXLETOL
(bempedoic acid) tablets

Adding nonstatin NEXLETOL once a day can

LEARN MORE >

© 2020 Esperion Therapeutics, Inc. All rights reserved. NEXL 20-0017, 02/20/20

NEXLETOL
(bempedoic acid) tablets

BREAK THE CYCLE

LEARN MORE >

© 2020 Esperion Therapeutics, Inc. All rights reserved. NEXL 20-0017, 02/20/20



FINANCIAL UPDATE

Rick Bartram, CFO

MOMENTUM ACROSS REVENUE STREAMS



**U.S. Net Product
Sales increased**

5X


quarter over quarter

**Ex-U.S.
Collaboration
Milestones**

**Ex-U.S.
Royalty
Revenues**

OUR FINANCIAL POSITION CONTINUES TO BUILD OVER TIME

Over \$1,000 Million in Future Non-Dilutive Funds



Key Financial Data	
FY Revenue	No Guidance Before 2022
FY 2020 R&D Guidance	\$135 - \$145
FY 2020 SG&A Guidance	\$200 - \$210 4Q 2020 inclusive of DTC campaign launch
FY 2020 Op Ex Guidance ⁽¹⁾	\$335 - \$355M
Common Shares Outstanding	Basic 27.8M; Fully Diluted 32.7M

¹ Excludes \$30M of non-cash stock based compensation expense

**LOOKING FORWARD, WE ALL
HAVE MUCH TO CELEBRATE**

Discussion & Questions

THANK YOU & QUESTIONS?



Tim Mayleben
CEO & President



Mark Glickman
CCO



Rick Bartram
CFO